Year |
Citation |
Score |
2021 |
Pawaskar D, Chen X, Glassman F, May F, Roberts A, Biondo M, McKenzie A, Nolte MW, Jusko WJ, Tortorici M. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312). Clinical and Translational Science. PMID 34811931 DOI: 10.1111/cts.13192 |
0.504 |
|
2013 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemotherapy and Pharmacology. 71: 1231-40. PMID 23455452 DOI: 10.1007/S00280-013-2117-X |
0.593 |
|
2013 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemotherapy and Pharmacology. 71: 1219-29. PMID 23455451 DOI: 10.1007/S00280-013-2116-Y |
0.555 |
|
2013 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ. Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation. Pharmaceutical Research. 30: 707-13. PMID 23151723 DOI: 10.1007/S11095-012-0909-Z |
0.543 |
|
2013 |
Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ. Interactions of everolimus and sorafenib in pancreatic cancer cells. The Aaps Journal. 15: 78-84. PMID 23054975 DOI: 10.1208/S12248-012-9417-7 |
0.552 |
|
2012 |
Pawaskar DK, Straubinger RM, Fetterly G, Hylander BH, Repasky EA, Ma WW, Jusko WJ. Abstract 3681: Multi-scale analysis of everolimus and sorafenib combination in pancreatic cancer xenografts Cancer Research. 72: 3681-3681. DOI: 10.1158/1538-7445.Am2012-3681 |
0.615 |
|
2012 |
Ma W, Weekes C, Pawaskar D, Fetterly G, Messersmith W, Dy G, Straubinger R, Jusko W, Eckhardt S, Adjei A. 584 Preclinical and Clinical Evaluation of the Combination of Sorafenib and Everolimus in Patients with Advanced Solid Tumors European Journal of Cancer. 48: 179. DOI: 10.1016/S0923-7534(20)33076-3 |
0.512 |
|
2011 |
Pawaskar DK, Straubinger R, Fetterly G, Ma W, Jusko W. Abstract 27: Physiologically based pharmacokinetic model for interactions of sorafenib and everolimus in mice Cancer Research. 71: 27-27. DOI: 10.1158/1538-7445.Am2011-27 |
0.583 |
|
2009 |
Woo S, Pawaskar D, Jusko WJ. Methods of utilizing baseline values for indirect response models. Journal of Pharmacokinetics and Pharmacodynamics. 36: 381-405. PMID 19697107 DOI: 10.1007/S10928-009-9128-6 |
0.477 |
|
Show low-probability matches. |